Wednesday, 11 December 2013
Monday, 9 December 2013
FDA and EMEA approve of Game Changer Sofosbuvir
Sofosbuvir
is a first-in-class polymerase inhibitor that allows for all-oral, interferon-free therapy for some patients with hepatitis C and reduced treatment time for most.
The US Food and Drug Administration (FDA) has approved the
first-in-kind nuceotide analog inhibitor sofosbuvir (Sovaldi, Gilead
Sciences, Inc) for the treatment of adults with chronic hepatitis C virus (HCV)
infection, a widely anticipated move that is expected to dramatically improve
outcomes for many patients.
The
European Medicines Agency's Committee for Medicinal Products for Human use
(CHMP) has recommended granting a marketing authorisation for Sovaldi
(sofosbuvir), for use 'in combination with other medicinal products for the
treatment of chronic (long-term) hepatitis C in adults'.
Friday, 6 December 2013
Clobazam
(Onfi) Can Cause Serious Skin Reactions, FDA Warns
The
antiseizure drug clobazam (Onfi, Lundbeck) can trigger rare but
potentially fatal skin reactions, the US Food and Drug Administration (FDA)
announced today.
For
clobazam, the skin reactions to watch for are Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN). Patients taking clobazam can experience these
disorders at any time, but the risk goes up during the first 8 weeks of
treatment or when treatment resumes after it was stopped. All the cases of
these 2 adverse events identified by the FDA landed patients in the hospital,
with 1 patient going
blind and another dying.
Thursday, 5 December 2013
Oral Cancer Screening
Squamous cell
carcinoma accounts for 90% of all cases of oral cavity and pharyngeal cancer.
More than half of persons with oral and pharyngeal cancer have regional or
distant metastases when they are first diagnosed. The USPSTF therefore stated
that screening for oral cancer may be helpful if potentially malignant
disorders can be identified earlier and treated successfully.
![]() |
| ORAL CANCER SCREENING METHODS |
Thursday, 28 November 2013
ACRI Clinical Research Institute - Accredited to University of Mysore!
Flash News! ACRI's Post Graduate Diploma in Clinical Research & Clinical Data Management course in now recognized by the University of Mysore.
Tuesday, 26 November 2013
Subscribe to:
Posts (Atom)






